Computational Immunology is a field of science that encompasses high-throughput genomic and bioinformatics approaches to immunology. The field's main aim is to convert immunological data into computational problems, solve these problems using mathematical and computational approaches and then convert these results into immunologically meaningful interpretations.
麻豆原创 Analysis and Insights: Global Computational Immunology 麻豆原创
The global Computational Immunology market is projected to grow from US$ million in 2023 to US$ million by 2029, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Computational Immunology is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The China market for Computational Immunology is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The Europe market for Computational Immunology is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global key companies of Computational Immunology include EpiVax, Novozymes Biopharma, ioGenetics, International Society of Vaccines, IMGT, Dassault Systemes, Certara, Chemical Computing Group and Compugen, etc. in 2022, the global top five players had a share approximately % in terms of revenue.
Report Includes
This report presents an overview of global market for Computational Immunology market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Computational Immunology, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Computational Immunology, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Computational Immunology revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Computational Immunology market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Computational Immunology revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including EpiVax, Novozymes Biopharma, ioGenetics, International Society of Vaccines, IMGT, Dassault Systemes, Certara, Chemical Computing Group and Compugen, etc.
By Company
EpiVax
Novozymes Biopharma
ioGenetics
International Society of Vaccines
IMGT
Dassault Systemes
Certara
Chemical Computing Group
Compugen
Genedata AG
Insilico Biotechnology AG
Leadscope Inc
Nimbus Discovery
Strand Life Sciences
Schrodinger
Simulation Plus
Rosa & Co
Segment by Type
Cancer Diagnosis & Therapy
Reverse Vaccinology
Immune System Modeling
Segment by Application
Allergy Prediction Databases
Analysis Resource Database
International Immunogenetics System
The Ontology of Immune Epitopes
Immune Epitope Database
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East, Africa, and Latin America
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Computational Immunology in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Computational Immunology companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Computational Immunology revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Computational Immunology 麻豆原创 Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Cancer Diagnosis & Therapy
1.2.3 Reverse Vaccinology
1.2.4 Immune System Modeling
1.3 麻豆原创 by Application
1.3.1 Global Computational Immunology 麻豆原创 Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Allergy Prediction Databases
1.3.3 Analysis Resource Database
1.3.4 International Immunogenetics System
1.3.5 The Ontology of Immune Epitopes
1.3.6 Immune Epitope Database
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Computational Immunology 麻豆原创 Perspective (2018-2029)
2.2 Global Computational Immunology Growth Trends by Region
2.2.1 Computational Immunology 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Computational Immunology Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Computational Immunology Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Computational Immunology 麻豆原创 Dynamics
2.3.1 Computational Immunology Industry Trends
2.3.2 Computational Immunology 麻豆原创 Drivers
2.3.3 Computational Immunology 麻豆原创 Challenges
2.3.4 Computational Immunology 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Computational Immunology by Players
3.1.1 Global Computational Immunology Revenue by Players (2018-2023)
3.1.2 Global Computational Immunology Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Computational Immunology 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Computational Immunology, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Computational Immunology 麻豆原创 Concentration Ratio
3.4.1 Global Computational Immunology 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Computational Immunology Revenue in 2022
3.5 Global Key Players of Computational Immunology Head office and Area Served
3.6 Global Key Players of Computational Immunology, Product and Application
3.7 Global Key Players of Computational Immunology, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Computational Immunology Breakdown Data by Type
4.1 Global Computational Immunology Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Computational Immunology Forecasted 麻豆原创 Size by Type (2024-2029)
5 Computational Immunology Breakdown Data by Application
5.1 Global Computational Immunology Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Computational Immunology Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Computational Immunology 麻豆原创 Size (2018-2029)
6.2 North America Computational Immunology 麻豆原创 Size by Type
6.2.1 North America Computational Immunology 麻豆原创 Size by Type (2018-2023)
6.2.2 North America Computational Immunology 麻豆原创 Size by Type (2024-2029)
6.2.3 North America Computational Immunology 麻豆原创 Share by Type (2018-2029)
6.3 North America Computational Immunology 麻豆原创 Size by Application
6.3.1 North America Computational Immunology 麻豆原创 Size by Application (2018-2023)
6.3.2 North America Computational Immunology 麻豆原创 Size by Application (2024-2029)
6.3.3 North America Computational Immunology 麻豆原创 Share by Application (2018-2029)
6.4 North America Computational Immunology 麻豆原创 Size by Country
6.4.1 North America Computational Immunology 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Computational Immunology 麻豆原创 Size by Country (2018-2023)
6.4.3 North America Computational Immunology 麻豆原创 Size by Country (2024-2029)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Computational Immunology 麻豆原创 Size (2018-2029)
7.2 Europe Computational Immunology 麻豆原创 Size by Type
7.2.1 Europe Computational Immunology 麻豆原创 Size by Type (2018-2023)
7.2.2 Europe Computational Immunology 麻豆原创 Size by Type (2024-2029)
7.2.3 Europe Computational Immunology 麻豆原创 Share by Type (2018-2029)
7.3 Europe Computational Immunology 麻豆原创 Size by Application
7.3.1 Europe Computational Immunology 麻豆原创 Size by Application (2018-2023)
7.3.2 Europe Computational Immunology 麻豆原创 Size by Application (2024-2029)
7.3.3 Europe Computational Immunology 麻豆原创 Share by Application (2018-2029)
7.4 Europe Computational Immunology 麻豆原创 Size by Country
7.4.1 Europe Computational Immunology 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Computational Immunology 麻豆原创 Size by Country (2018-2023)
7.4.3 Europe Computational Immunology 麻豆原创 Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Computational Immunology 麻豆原创 Size (2018-2029)
8.2 China Computational Immunology 麻豆原创 Size by Type
8.2.1 China Computational Immunology 麻豆原创 Size by Type (2018-2023)
8.2.2 China Computational Immunology 麻豆原创 Size by Type (2024-2029)
8.2.3 China Computational Immunology 麻豆原创 Share by Type (2018-2029)
8.3 China Computational Immunology 麻豆原创 Size by Application
8.3.1 China Computational Immunology 麻豆原创 Size by Application (2018-2023)
8.3.2 China Computational Immunology 麻豆原创 Size by Application (2024-2029)
8.3.3 China Computational Immunology 麻豆原创 Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Computational Immunology 麻豆原创 Size (2018-2029)
9.2 Asia Computational Immunology 麻豆原创 Size by Type
9.2.1 Asia Computational Immunology 麻豆原创 Size by Type (2018-2023)
9.2.2 Asia Computational Immunology 麻豆原创 Size by Type (2024-2029)
9.2.3 Asia Computational Immunology 麻豆原创 Share by Type (2018-2029)
9.3 Asia Computational Immunology 麻豆原创 Size by Application
9.3.1 Asia Computational Immunology 麻豆原创 Size by Application (2018-2023)
9.3.2 Asia Computational Immunology 麻豆原创 Size by Application (2024-2029)
9.3.3 Asia Computational Immunology 麻豆原创 Share by Application (2018-2029)
9.4 Asia Computational Immunology 麻豆原创 Size by Region
9.4.1 Asia Computational Immunology 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Computational Immunology 麻豆原创 Size by Region (2018-2023)
9.4.3 Asia Computational Immunology 麻豆原创 Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Computational Immunology 麻豆原创 Size (2018-2029)
10.2 Middle East, Africa, and Latin America Computational Immunology 麻豆原创 Size by Type
10.2.1 Middle East, Africa, and Latin America Computational Immunology 麻豆原创 Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Computational Immunology 麻豆原创 Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Computational Immunology 麻豆原创 Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Computational Immunology 麻豆原创 Size by Application
10.3.1 Middle East, Africa, and Latin America Computational Immunology 麻豆原创 Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Computational Immunology 麻豆原创 Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Computational Immunology 麻豆原创 Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Computational Immunology 麻豆原创 Size by Country
10.4.1 Middle East, Africa, and Latin America Computational Immunology 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Computational Immunology 麻豆原创 Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Computational Immunology 麻豆原创 Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 EpiVax
11.1.1 EpiVax Company Details
11.1.2 EpiVax Business Overview
11.1.3 EpiVax Computational Immunology Introduction
11.1.4 EpiVax Revenue in Computational Immunology Business (2018-2023)
11.1.5 EpiVax Recent Developments
11.2 Novozymes Biopharma
11.2.1 Novozymes Biopharma Company Details
11.2.2 Novozymes Biopharma Business Overview
11.2.3 Novozymes Biopharma Computational Immunology Introduction
11.2.4 Novozymes Biopharma Revenue in Computational Immunology Business (2018-2023)
11.2.5 Novozymes Biopharma Recent Developments
11.3 ioGenetics
11.3.1 ioGenetics Company Details
11.3.2 ioGenetics Business Overview
11.3.3 ioGenetics Computational Immunology Introduction
11.3.4 ioGenetics Revenue in Computational Immunology Business (2018-2023)
11.3.5 ioGenetics Recent Developments
11.4 International Society of Vaccines
11.4.1 International Society of Vaccines Company Details
11.4.2 International Society of Vaccines Business Overview
11.4.3 International Society of Vaccines Computational Immunology Introduction
11.4.4 International Society of Vaccines Revenue in Computational Immunology Business (2018-2023)
11.4.5 International Society of Vaccines Recent Developments
11.5 IMGT
11.5.1 IMGT Company Details
11.5.2 IMGT Business Overview
11.5.3 IMGT Computational Immunology Introduction
11.5.4 IMGT Revenue in Computational Immunology Business (2018-2023)
11.5.5 IMGT Recent Developments
11.6 Dassault Systemes
11.6.1 Dassault Systemes Company Details
11.6.2 Dassault Systemes Business Overview
11.6.3 Dassault Systemes Computational Immunology Introduction
11.6.4 Dassault Systemes Revenue in Computational Immunology Business (2018-2023)
11.6.5 Dassault Systemes Recent Developments
11.7 Certara
11.7.1 Certara Company Details
11.7.2 Certara Business Overview
11.7.3 Certara Computational Immunology Introduction
11.7.4 Certara Revenue in Computational Immunology Business (2018-2023)
11.7.5 Certara Recent Developments
11.8 Chemical Computing Group
11.8.1 Chemical Computing Group Company Details
11.8.2 Chemical Computing Group Business Overview
11.8.3 Chemical Computing Group Computational Immunology Introduction
11.8.4 Chemical Computing Group Revenue in Computational Immunology Business (2018-2023)
11.8.5 Chemical Computing Group Recent Developments
11.9 Compugen
11.9.1 Compugen Company Details
11.9.2 Compugen Business Overview
11.9.3 Compugen Computational Immunology Introduction
11.9.4 Compugen Revenue in Computational Immunology Business (2018-2023)
11.9.5 Compugen Recent Developments
11.10 Genedata AG
11.10.1 Genedata AG Company Details
11.10.2 Genedata AG Business Overview
11.10.3 Genedata AG Computational Immunology Introduction
11.10.4 Genedata AG Revenue in Computational Immunology Business (2018-2023)
11.10.5 Genedata AG Recent Developments
11.11 Insilico Biotechnology AG
11.11.1 Insilico Biotechnology AG Company Details
11.11.2 Insilico Biotechnology AG Business Overview
11.11.3 Insilico Biotechnology AG Computational Immunology Introduction
11.11.4 Insilico Biotechnology AG Revenue in Computational Immunology Business (2018-2023)
11.11.5 Insilico Biotechnology AG Recent Developments
11.12 Leadscope Inc
11.12.1 Leadscope Inc Company Details
11.12.2 Leadscope Inc Business Overview
11.12.3 Leadscope Inc Computational Immunology Introduction
11.12.4 Leadscope Inc Revenue in Computational Immunology Business (2018-2023)
11.12.5 Leadscope Inc Recent Developments
11.13 Nimbus Discovery
11.13.1 Nimbus Discovery Company Details
11.13.2 Nimbus Discovery Business Overview
11.13.3 Nimbus Discovery Computational Immunology Introduction
11.13.4 Nimbus Discovery Revenue in Computational Immunology Business (2018-2023)
11.13.5 Nimbus Discovery Recent Developments
11.14 Strand Life Sciences
11.14.1 Strand Life Sciences Company Details
11.14.2 Strand Life Sciences Business Overview
11.14.3 Strand Life Sciences Computational Immunology Introduction
11.14.4 Strand Life Sciences Revenue in Computational Immunology Business (2018-2023)
11.14.5 Strand Life Sciences Recent Developments
11.15 Schrodinger
11.15.1 Schrodinger Company Details
11.15.2 Schrodinger Business Overview
11.15.3 Schrodinger Computational Immunology Introduction
11.15.4 Schrodinger Revenue in Computational Immunology Business (2018-2023)
11.15.5 Schrodinger Recent Developments
11.16 Simulation Plus
11.16.1 Simulation Plus Company Details
11.16.2 Simulation Plus Business Overview
11.16.3 Simulation Plus Computational Immunology Introduction
11.16.4 Simulation Plus Revenue in Computational Immunology Business (2018-2023)
11.16.5 Simulation Plus Recent Developments
11.17 Rosa & Co
11.17.1 Rosa & Co Company Details
11.17.2 Rosa & Co Business Overview
11.17.3 Rosa & Co Computational Immunology Introduction
11.17.4 Rosa & Co Revenue in Computational Immunology Business (2018-2023)
11.17.5 Rosa & Co Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
EpiVax
Novozymes Biopharma
ioGenetics
International Society of Vaccines
IMGT
Dassault Systemes
Certara
Chemical Computing Group
Compugen
Genedata AG
Insilico Biotechnology AG
Leadscope Inc
Nimbus Discovery
Strand Life Sciences
Schrodinger
Simulation Plus
Rosa & Co
听
听
*If Applicable.
